At the American Academy of Ophthalmology (AAO) 2026 Retina Subspecialty Day in New Orleans, Charles C. Wykoff, MD, PhD, presented 1-year primary end point results from the phase 3 DAYBREAK trial.
Charles C. Wykoff, MD, PhD
Advertisement
Articles by Charles C. Wykoff, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves subcutaneous Enspryng for TED
2
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
3
OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplant
4
EC-104 outperforms Ozurdex in phase 2 BETTIS-1 trial for anti-VEGF–resistant DME
5